BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Shares Bought by Algert Global LLC

Algert Global LLC boosted its stake in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 40.5% during the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 725,305 shares of the biotechnology company's stock after buying an additional 209,096 shares during the quarter. Algert Global LLC owned approximately 0.35% of BioCryst Pharmaceuticals worth $5,454,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. Vanguard Group Inc. lifted its stake in BioCryst Pharmaceuticals by 7.8% during the fourth quarter. Vanguard Group Inc. now owns 21,890,422 shares of the biotechnology company's stock worth $164,616,000 after purchasing an additional 1,583,826 shares during the last quarter. Caligan Partners LP boosted its stake in shares of BioCryst Pharmaceuticals by 16.0% during the 4th quarter. Caligan Partners LP now owns 2,995,932 shares of the biotechnology company's stock worth $22,529,000 after acquiring an additional 412,347 shares in the last quarter. Northern Trust Corp raised its holdings in shares of BioCryst Pharmaceuticals by 7.7% during the fourth quarter. Northern Trust Corp now owns 2,004,911 shares of the biotechnology company's stock valued at $15,077,000 after acquiring an additional 143,986 shares during the period. Eversept Partners LP lifted its holdings in shares of BioCryst Pharmaceuticals by 269.9% in the fourth quarter. Eversept Partners LP now owns 1,980,312 shares of the biotechnology company's stock valued at $14,892,000 after purchasing an additional 1,444,907 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. increased its holdings in shares of BioCryst Pharmaceuticals by 4.9% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 1,979,992 shares of the biotechnology company's stock valued at $14,890,000 after purchasing an additional 91,998 shares during the period. Hedge funds and other institutional investors own 85.88% of the company's stock.

BioCryst Pharmaceuticals Price Performance

Shares of BCRX stock traded up $0.06 during trading hours on Friday, reaching $9.98. 7,606,302 shares of the company traded hands, compared to its average volume of 2,989,382. BioCryst Pharmaceuticals, Inc. has a 12-month low of $5.34 and a 12-month high of $11.11. The company has a market cap of $2.09 billion, a P/E ratio of -16.36 and a beta of 1.08. The firm has a 50-day moving average price of $7.87 and a 200 day moving average price of $7.89.

BioCryst Pharmaceuticals (NASDAQ:BCRX - Get Free Report) last announced its quarterly earnings data on Monday, February 24th. The biotechnology company reported ($0.13) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.07) by ($0.06). The business had revenue of $131.50 million for the quarter, compared to analyst estimates of $126.64 million. During the same period in the prior year, the firm posted $0.28 earnings per share. BioCryst Pharmaceuticals's revenue was up 40.8% compared to the same quarter last year. Sell-side analysts predict that BioCryst Pharmaceuticals, Inc. will post -0.36 EPS for the current year.

Analyst Ratings Changes

BCRX has been the subject of several research analyst reports. JPMorgan Chase & Co. boosted their price objective on BioCryst Pharmaceuticals from $10.00 to $13.00 and gave the stock an "overweight" rating in a research report on Tuesday, May 6th. Evercore ISI increased their target price on shares of BioCryst Pharmaceuticals from $10.00 to $12.00 and gave the stock an "outperform" rating in a research report on Monday, January 13th. Cantor Fitzgerald began coverage on shares of BioCryst Pharmaceuticals in a research note on Tuesday, April 29th. They issued an "overweight" rating and a $20.00 target price for the company. Barclays raised their target price on shares of BioCryst Pharmaceuticals from $8.00 to $11.00 and gave the company an "equal weight" rating in a research note on Wednesday. Finally, HC Wainwright reissued a "buy" rating and set a $30.00 price objective on shares of BioCryst Pharmaceuticals in a research note on Tuesday, May 6th. One analyst has rated the stock with a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, BioCryst Pharmaceuticals presently has a consensus rating of "Buy" and a consensus target price of $16.56.

BioCryst Pharmaceuticals Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.